Cell Therapeutics Expands its Late-Stage Oncology Pipeline with Chroma Therapeutics’ Tosedostat
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 3 (Table of Contents)
Published: 28 Mar-2011
DOI: 10.3833/pdr.v2011.i3.1449 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Cell Therapeutics (CTI) has licensed exclusive marketing and co-development rights in North, Central and South America to Chroma Therapeutics’ late-stage cancer drug, tosedostat, which will be initially developed for acute myeloid leukaemia, myelodysplastic syndrome and multiple myeloma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS